P
Precigen, Inc. (PGEN)
NMS – Real vaqt narxi. Valyuta: USD
4.08
-0.12 (-2.86%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
4.08
-0.12 (-2.86%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Precigen, Inc. — bu kashfiyot va klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, u immüno-onkologiya, autoimmun kasalliklar va yuqumli kasalliklar sohalaridagi kasalliklarni aniqlash uchun aniqlik texnologiyasidan foydalangan holda gen va hujayra terapiyalarini ishlab chiqadi. Kompaniya terapevtik platformalarni taqdim etadi, jumladan AdenoVerse platformasi, u terapevtik effektorlar, immunomodulyatorlar va vaktsina antigenni genli yetkazib berish uchun xususiy adenovektorlar kutubxonasidan foydalanadi; va UltraCAR-T saraton bemorlari uchun ximerik antigen retseptorli T-hujayra terapiyalarini ta'minlaydi. Shuningdek, u UltraCAR-T platformasiga asoslangan dasturlarni ishlab chiqadi, shu jumladan ilg'or tuxumdon, bachadon naychasi yoki birlamchi peritoneal saratonni davolash uchun 1/1b bosqichli klinik sinovda PRGN-3005; takrorlanuvchi yoki refrakter o'tkir miyeloid leykemiya va yuqori xavfli mielodisplastik sindromlari bo'lgan bemorlar uchun 1b bosqichli sinovda PRGN-3006; va ilg'or retseptor tirozin kinaz-o'xshash yotgan retseptor 1-musbat, gematologik va qattiq o'smalarni davolash uchun 1/1b bosqichli sinovda PRGN-3007. Bundan tashqari, kompaniya AdenoVerse immunoterapiya platformasiga asoslangan dasturlarni ishlab chiqmoqda, shu jumladan OIV+ qattiq o'smalari bo'lgan bemorlar uchun 2-bosqichli sinovda PRGN-2009; va takrorlanuvchi respirator papillomatozni davolash uchun ½ bosqichli sinovda PRGN-2012. Bundan tashqari, u o'zining xususiy elektroporatsiya moslamasi bo'lgan UltraPorator'ni taqdim etadi. Kompaniya ilgari Intrexon Corporation nomi bilan tanilgan va 2020-yil fevral oyida Precigen, Inc. nomini o'zgartirgan. Precigen, Inc. 1998-yilda tashkil etilgan va uning shtab-kvartirasi Germantown, Merilendda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bryan T. Butman Ph.D. | Senior VP & Head of CMC |
| Dr. Douglas E. Brough Ph.D. | Senior VP & Head of Research |
| Dr. Helen Sabzevari MPH, Ph.D. | President, CEO & Director |
| Mr. Donald P. Lehr J.D., Ph.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Harry Thomasian Jr. | Chief Financial Officer |
| Mr. Phil Tennant | Chief Commercial Officer |
| Mr. Randal J. Kirk J.D. | Executive Chairman |
| Mr. Rob Russell | VP & Head of Human Resources |
| Mr. Rutul R. Shah | Chief Operating Officer |
| Mr. Steven M. Harasym | VP & Head of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | ny20068828x1_def14a.htm |
| 2026-03-25 | 8-K | dp244075_8k.htm |
| 2025-11-13 | 10-Q | pgen-20250930.htm |
| 2025-09-17 | CORRESP | filename1.htm |
| 2025-09-03 | 8-K | tm2524946d1_8k.htm |
| 2025-08-19 | S-3 | dp233112_s3.htm |
| 2025-08-18 | 8-K | dp233151_8k.htm |
| 2025-08-12 | 10-Q | pgen-20250630.htm |
| 2025-06-30 | 8-K | dp230886_8k.htm |
| 2025-05-16 | DEF 14A | edge20046423x2_def14a.htm |